grepcent public filings, reorganized for comparison

Lifevantage Corp (LFVN)

CIK: 0000849146. SIC: 2834 Pharmaceutical Preparations. Latest 10-K as of: 2026-08-27.

SIC breadcrumb: Manufacturing > Chemicals And Allied Products > SIC 2834 Pharmaceutical Preparations

SEC company page: https://www.sec.gov/edgar/browse/?CIK=849146. Latest filing source: 0001193125-26-371257.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2026 · period end 2026-06-30 · filed 2026-08-27 · accession 0001193125-26-371257 · source: SEC companyfacts

Revenue
182,586,000 USD verified
Net income
5,072,000 USD verified
Assets
62,111,000 USD verified
Free cash flow
6,670,000 USD computed
Net margin
2.78% computed
Operating margin
3.34% computed
Revenue YoY
-20.10% computed
ROE
15.10% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

LFVN ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 2834; per-ratio N printed.LFVN ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 2834; per-ratio N printed.RatioLFVNPeer medianPercentileNNet margin2.8%1.0%53107Operating margin3.3%-1.3%53100Revenue growth-20.1%14.7%13127FCF margin3.7%-14.0%60127ROE15.1%-30.2%83171ROA8.2%-21.8%85187Liabilities / equity0.850.3865173Current ratio1.894.8912188

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue182,586,000USD20262026-08-27
Net income5,072,000USD20262026-08-27
Assets62,111,000USD20262026-08-27

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-27. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000849146.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric20162017201820192020202120222023202420252026
Revenue199,489,000203,204,000225,958,000232,915,000220,181,000206,360,000213,398,000200,164,000228,530,000182,586,000
Net income1,608,0005,761,0007,429,00011,549,00012,894,0003,120,0002,540,0002,937,0009,805,0005,072,000
Operating income4,449,00010,323,0009,814,00015,466,00017,615,0007,575,0004,259,0004,332,00012,199,0006,100,000
Gross profit166,033,000168,356,000187,985,000194,951,000181,994,000168,263,000170,011,000158,724,000183,666,000141,613,000
Diluted EPS0.110.410.500.790.900.240.200.230.750.40
Operating cash flow6,597,00013,256,00017,789,00018,326,00016,273,0007,959,0006,828,00012,197,00011,878,00010,241,000
Capital expenditures1,055,0004,649,0002,506,0002,681,0003,741,0001,530,0003,067,0002,245,0001,371,0003,571,000
Dividends paid0.000.00378,0001,586,0006,940,0002,067,0002,344,000
Share buybacks0.001,500,0004,655,0005,405,00011,933,0008,833,000822,0006,430,0003,147,0002,043,000
Assets45,249,00051,142,00055,273,00058,877,00078,732,00070,706,00066,123,00060,299,00071,958,00062,111,000
Liabilities30,722,00029,195,00028,074,00025,623,00041,925,00039,190,00031,474,00034,308,00037,317,00028,522,000
Stockholders' equity14,527,00021,947,00027,199,00033,254,00036,807,00031,516,00034,649,00025,991,00034,641,00033,589,000
Cash and cash equivalents7,883,00011,458,00016,652,00018,824,00022,138,00023,174,00020,190,00021,605,00016,886,00020,201,000
Free cash flow5,542,0008,607,00015,283,00015,645,00012,532,0006,429,0003,761,0009,952,00010,507,0006,670,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric20162017201820192020202120222023202420252026
Net margin0.81%2.84%3.29%4.96%5.86%1.51%1.19%1.47%4.29%2.78%
Operating margin2.23%5.08%4.34%6.64%8.00%3.67%2.00%2.16%5.34%3.34%
Return on equity11.07%26.25%27.31%34.73%35.03%9.90%7.33%11.30%28.30%15.10%
Return on assets3.55%11.26%13.44%19.62%16.38%4.41%3.84%4.87%13.63%8.17%
Liabilities / equity2.111.331.030.771.141.240.911.321.080.85
Current ratio1.521.641.651.751.911.832.261.691.871.89

Industry Peer Context

Each number-line places LFVN against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

LFVN Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 107.LFVN Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 107.107 SIC peersMin -146.0%Median 1.0%Max 124.7%LFVN 2.8%

Operating margin peer context

LFVN Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 100.LFVN Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 100.100 SIC peersMin -149.3%Median -1.3%Max 65.6%LFVN 3.3%

ROE peer context

LFVN ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 171.LFVN ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 171.171 SIC peersMin -441.6%Median -30.2%Max 128.7%LFVN 15.1%

ROA peer context

LFVN ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 187.LFVN ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2834; peer count 187.187 SIC peersMin -163.7%Median -21.8%Max 71.5%LFVN 8.2%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

LFVN FY2026 income statement bridge from reported figures.LFVN FY2026 income statement bridge from reported figures.LFVN income bridgeFY2026: revenue to net incomeSource: SEC companyfacts FY2026.Income statement bridgeReported amount$0.0B$125.0M$250.0M$182.6MRevenue-$41.0MCost$141.6MGross-$135.5MOpEx$6.1MOperating-$1.0MOther/tax$5.1MNet income

Figure provenance: SEC companyfacts FY 2026. Revenue: accession 0001193125-26-371257; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001193125-26-371257; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001193125-26-371257; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001193125-26-371257; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

LFVN FY2026 free cash flow bridge from reported figures.LFVN FY2026 free cash flow bridge from reported figures.LFVN free cash flow bridgeFY2026: operating cash flow less capital expendituresSource: SEC companyfacts FY2026.Free cash flow bridgeReported amount$0.0B$125.0M$250.0M$10.2MOperating cash flow-$3.6MCapex$6.7MFree cash flow

Figure provenance: SEC companyfacts FY 2026. Operating cash flow: accession 0001193125-26-371257; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001193125-26-371257; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001193125-26-371257; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

LFVN revenue, last 5 periods. Source: SEC companyfacts FY2026.LFVN revenue, last 5 periods. Source: SEC companyfacts FY2026.LFVN RevenueLatest point: FY2026 = $182.6MSource: SEC companyfacts FY2026.Fiscal yearReported revenue$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

LFVN net income, last 5 periods. Source: SEC companyfacts FY2026.LFVN net income, last 5 periods. Source: SEC companyfacts FY2026.LFVN Net incomeLatest point: FY2026 = $5.1MSource: SEC companyfacts FY2026.Fiscal yearNet income$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

LFVN operating income, last 5 periods. Source: SEC companyfacts FY2026.LFVN operating income, last 5 periods. Source: SEC companyfacts FY2026.LFVN Operating incomeLatest point: FY2026 = $6.1MSource: SEC companyfacts FY2026.Fiscal yearOperating income$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

LFVN gross profit, last 5 periods. Source: SEC companyfacts FY2026.LFVN gross profit, last 5 periods. Source: SEC companyfacts FY2026.LFVN Gross profitLatest point: FY2026 = $141.6MSource: SEC companyfacts FY2026.Fiscal yearGross profit$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

LFVN diluted eps, last 5 periods. Source: SEC companyfacts FY2026.LFVN diluted eps, last 5 periods. Source: SEC companyfacts FY2026.LFVN Diluted EPSLatest point: FY2026 = $0.40/shareSource: SEC companyfacts FY2026.Fiscal yearDiluted EPS (USD/share)$0.00/share$0.50/share$1.00/shareFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

LFVN operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.LFVN operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.LFVN Operating cash flowLatest point: FY2026 = $10.2MSource: SEC companyfacts FY2026.Fiscal yearOperating cash flow$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

LFVN capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.LFVN capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.LFVN Capital expendituresLatest point: FY2026 = $3.6MSource: SEC companyfacts FY2026.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

LFVN dividends paid, last 5 periods. Source: SEC companyfacts FY2026.LFVN dividends paid, last 5 periods. Source: SEC companyfacts FY2026.LFVN Dividends paidLatest point: FY2026 = $2.3MSource: SEC companyfacts FY2026.Fiscal yearDividends paid$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: PaymentsOfDividends. Source concepts: us-gaap:PaymentsOfDividends.

LFVN share buybacks, last 5 periods. Source: SEC companyfacts FY2026.LFVN share buybacks, last 5 periods. Source: SEC companyfacts FY2026.LFVN Share buybacksLatest point: FY2026 = $2.0MSource: SEC companyfacts FY2026.Fiscal yearShare buybacks$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

LFVN assets, last 5 periods. Source: SEC companyfacts FY2026.LFVN assets, last 5 periods. Source: SEC companyfacts FY2026.LFVN AssetsLatest point: FY2026 = $62.1MSource: SEC companyfacts FY2026.Fiscal yearAssets$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: Assets. Source concepts: us-gaap:Assets.

LFVN liabilities, last 5 periods. Source: SEC companyfacts FY2026.LFVN liabilities, last 5 periods. Source: SEC companyfacts FY2026.LFVN LiabilitiesLatest point: FY2026 = $28.5MSource: SEC companyfacts FY2026.Fiscal yearLiabilities$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

LFVN stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.LFVN stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.LFVN Stockholders' equityLatest point: FY2026 = $33.6MSource: SEC companyfacts FY2026.Fiscal yearStockholders' equity$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

LFVN cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.LFVN cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.LFVN Cash and cash equivalentsLatest point: FY2025 = $20.2MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-06-30; accession 0000849146-25-000068; filed 2025-09-04. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

LFVN free cash flow, last 5 periods. Source: SEC companyfacts FY2026.LFVN free cash flow, last 5 periods. Source: SEC companyfacts FY2026.LFVN Free cash flowLatest point: FY2026 = $6.7MSource: SEC companyfacts FY2026.Fiscal yearFree cash flow$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-27. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000849146.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-03-310.09reported discrete quarter
2023-Q12022-09-300.05reported discrete quarter
2023-Q22023-03-310.08reported discrete quarter
2024-Q12023-09-3051,364,000629,0000.05reported discrete quarter
2024-Q22023-09-30629,000reported discrete quarter
2024-Q22023-12-3151,624,000-0.05reported discrete quarter
2024-Q32023-12-31-656,000reported discrete quarter
2024-Q32024-03-3148,245,0000.13reported discrete quarter
2024-Q42024-06-3048,931,0001,305,000derived Q4 = FY annual - nine-month YTD
2025-Q12024-09-3047,214,0001,826,0000.14reported discrete quarter
2025-Q22024-09-301,826,000reported discrete quarter
2025-Q22024-12-3167,762,0000.19reported discrete quarter
2025-Q32024-12-312,550,000reported discrete quarter
2025-Q32025-03-3158,440,0000.26reported discrete quarter
2025-Q42025-06-3055,114,0001,959,000derived Q4 = FY annual - nine-month YTD
2026-Q12025-09-3047,561,0002,155,0000.17reported discrete quarter
2026-Q22025-09-302,155,000reported discrete quarter
2026-Q22025-12-3148,931,0000.02reported discrete quarter
2026-Q32025-12-31276,000reported discrete quarter
2026-Q32026-03-3143,716,0000.11reported discrete quarter
2026-Q42026-06-3042,377,0001,279,000derived Q4 = FY annual - nine-month YTD

Quarterly Charts

LFVN quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.LFVN quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.LFVN Quarterly RevenueLatest point: 2026-Q4 = $42.4MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Revenue$0.0B$125.0M$250.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

LFVN quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.LFVN quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.LFVN Quarterly Net incomeLatest point: 2026-Q4 = $1.3MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001193125-26-371257; filed 2026-08-27. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

LFVN quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.LFVN quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.LFVN Quarterly Diluted EPSLatest point: 2026-Q3 = $0.11/shareSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Diluted EPS (USD/share)-$0.50/share$0.00/share$0.50/share2022-Q32023-Q12023-Q22024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q22026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001193125-26-208922; filed 2026-05-06. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read LFVN's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read LFVN's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001193125-26-208922.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-05-06. Report date: 2026-03-31.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. We are dedicated to helping people achieve their health, wellness, and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. We currently sell our products to customers and independent consultants in two geographic regions that we have classified as the Americas region and the Asia/Pacific and Europe region.

The success and growth of our business is primarily based on the effectiveness of our independent consultants to attract and retain customers in order to sell our products and our ability to attract and retain independent consultants. When we are successful in attracting and retaining independent consultants and customers, it is largely because of:

•
Our products, including our flagship Protandim® family of scientifically validated dietary supplements, our LifeVantage® family of dietary supplements that include the MindBody GLP-1 System®, Omega+, ProBio, IC Bright®, the Rise AM & Reset PM System®, D3+, and Daily Wellness, our PhysIQ™ Fat Burn and Prebiotic dietary supplements, our TrueScience® line of skin and hair care products and Liquid Collagen, Petandim®, our companion pet supplement formulated to combat oxidative stress in dogs; AXIO®, our nootropic energy drink mixes; and LoveBiome® P84 and PhytoPower B, dietary supplements acquired pursuant to the purchase of LoveBiome’s critical assets formulated to support gut health.

•
Our sales compensation plan and other sales initiatives and incentives; and

•
Our delivery of superior customer service.

As a result, it is vital to our success that we leverage our product development resources to develop and introduce compelling and innovative products and provide opportunities for our independent consultants to sell these products in a variety of markets. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore and Iceland. In addition, we sell our products in a number of countries for personal consumption only. Entering a new market requires a considerable amount of time, resources and continued support. If we are unable to properly support an existing or new market, our revenue growth may be negatively impacted. On June 30, 2025, we ceased operations in the Philippines and closed that market. In September 2025, we commenced operations in Iceland.

Our Products

Our products are: the Protandim® line of scientifically validated dietary supplements; the LifeVantage® line of dietary supplements that include the MindBody GLP-1 System®, Omega+, ProBio, IC Bright®, the Rise AM & Reset PM System®, D3+, and Daily Wellness; the PhysIQ Fat Burn and Prebiotic dietary supplements; the TrueScience® line of skin and hair care products and Liquid Collagen; the Petandim® companion pet supplement formulated to combat oxidative stress in dogs; AXIO®, our nootropic energy drink mixes; and LoveBiome® P84 and PhytoPower B, dietary supplements acquired pursuant to the purchase of LoveBiome’s critical assets formulated to support gut health. We believe the significant number of customers who regularly and repeatedly purchase our products is a strong indicator of the health benefits of our products.

24

The Protandim® product line includes Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, and Protandim® NAD Synergizer®. The Protandim® NRF1 Synergizer® is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim® Nrf2 Synergizer® contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body’s natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective antioxidant enzymes, including superoxide dismutase, catalase, and glutathione synthase. The Protandim® NAD Synergizer® was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide), and it has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity, and mood. Use of the three Protandim® products together, marketed as the Protandim® Tri-Synergizer®, has been shown to produce synergistic benefits greater than using the single products on their own.

The LifeVantage® product line includes: the new MindBody GLP-1 System®, a dietary supplement that combines two products MB Core™ and MB Enhance™ designed to support weight loss and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system; ProBio, a dietary supplement designed to support optimal digestion and immune system function; Daily Wellness, a dietary supplement designed to support immune health. IC Bright®, a dietary supplement to help support eye and brain health, reduce eye fatigue and strain, support cognitive functions, and may help support normal sleep patterns; the Rise AM & Reset PM System®, a dietary supplement that uses Timewise Nutrient Delivery™ to provide the body with the right nutrients in the right amounts at the right time and D3+, a dietary supplement that provides vitamin D3, vitamin K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health.

PhysIQ™ Fat Burn is a dietary supplement designed to support weight management, and PhysIQ™ Prebiotic is a dietary supplement designed to support a healthy digestive tract.

Our TrueScience® line of skin and hair care products includes TrueScience® TrueClean Refining Cleanser, TrueScience® TrueRenew Daily Firming Complex, TrueScience® TrueLift Illuminating Eye Cream, TrueScience® TrueHydrate Brightening Moisturizer, TrueScience® TrueTone Perfecting Lotion, TrueScience® TrueProtect Daily Mineral Sunstick SPF 30, TrueScience® Perfecting Lotion, TrueScience® Hand Cream, TrueScience® Invigorating Shampoo, TrueScience® Nourishing Conditioner, TrueScience® Scalp Serum, and TrueScience® Liquid Collagen, a dietary supplement that activates, replenishes, and maintains collagen to support firmness and elasticity from within.

Petandim® is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation.

AXIO® is our line of our nootropic energy drink mixes formulated to promote alertness and support mental performance.

LoveBiome® P84 is a dietary supplement formulated to activate 14 key peptides that regulate, repair, and restore gut health. PhytoPower B is a dietary supplement formulated to slow carb-to-sugar conversion and support healthy metabolism.

We sell our products both individually and in stacks. A stack consists of multiple products bundled together that are designed to achieve a specific result. In fiscal year 2025, our stack strategy continued to focus on the brand message of activation. During the year, we introduced a number of new stacks to meet customer and independent consultant needs. Prior to the launch of our latest activator, the MindBody GLP-1 System®, we introduced the Kickstart Bundle, which features a selection of products (varies by market) to help prepare the body for GLP-1 activation. Additionally, several stacks were introduced that incorporated the MindBody GLP-1 System® to offer consumers support for weight management and wellness along with delivering other targeted benefits as part of their activated lifestyle.

We also introduced our Healthy Weight Stack, which includes the MindBody GLP-1 System® and Protandim® Nrf2 Synergizer®. Results of an in vitro study were released that showed beneficial “activation synergies” when both products were used together, including enhanced fatty acid metabolism, improved defense against oxidative stress, and activation of 22 new genes that help cells make what they need to support organ strength, structure, and signaling.

Subsequent to acquiring the critical assets of LoveBiome, we introduced our Healthy Edge Stack, which includes Protandim® Nrf2 Synergizer® and LoveBiome® P84; and our Healthy Edge + MindBody GLP-1 System Stack, which includes Protandim® Nrf2 Synergizer®, the MindBody GLP-1 System® and LoveBiome® P84.

25

We continue to offer other popular stacks with products that complement one another with inner activation power for internal benefits that can be felt, external benefits that can be seen, or both.

We currently have additional products in development and additional product offerings that come with our acquisition of LoveBiome’s critical assets in October 2025. Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our ability to attract new independent consultants and customers.

Compensation Plan for our Independent Consultants

On March 1, 2023, we launched a new compensation plan for our independent consultants in the United States, Japan, Australia, and New Zealand markets. We refer to this compensation plan as our Evolve Compensation Plan. On February 1, 2024, we launched the Evolve Compensation Plan in the Canada, Mexico, and Europe markets. On November 1, 2024, we launched an optimized version of the Evolve Compensation Plan in the United States, Japan, Australia, New Zealand, Canada, Mexico, and Europe markets. On March 1, 2025, we launched the Evolve Compensation Plan in other markets, including Taiwan, Hong Kong, and Singapore. In September 2025, we launched Iceland with the Evolve Compensation Plan and plan to do the same in any new markets.

Accounts

Because we primarily utilize a direct selling model for the distribution of a majority of our products, the success and growth of our business depends in large part on the effectiveness of our independent consultants to attract and retain customers to purchase our products and our ability to attract new and retain existing independent consultants. Changes in our product sales typically are the result of variations in product sales volume relating to fluctuations in the number of active independent consultants and customers purchasing our products. The number of active independent consultants and customers is, therefore, used by management as a key non-financial measure.

The following tables summarize the changes in our active accounts base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we define “Active Accounts” as only those independent consultants and customers who have purchased from us at any time during the most recent three-month period, either for personal use or for resale.

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001193125-26-371257. The complete FY 2026 MD&A is published at /company/LFVN/mda/fy2026/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-08-27. Report date: 2026-06-30.

ITEM 7 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes, which are included in this Annual Report on Form 10-K.

Overview

We are a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. We are dedicated to helping people achieve their health, wellness, and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, gut health products, skin and hair care products, and nootropics. We currently sell our products to customers and independent consultants in two geographic regions that we have classified as the Americas region and the Asia/Pacific and Europe region.

The success and growth of our business is primarily based on the effectiveness of our independent consultants to attract and retain customers in order to sell our products and our ability to attract and retain independent consultants. When we are successful in attracting and retaining independent consultants and customers, it is largely because of:

•
Our products, including our flagship Protandim® family of scientifically validated dietary supplements, our LifeVantage® family of dietary supplements that include the MindBody GLP-1 System®, Omega+, ProBio, IC Bright®, the Rise AM & Reset PM System®, D3+, Daily Wellness, Fat Burn, Prebiotic and Carb Block, our newest activator the P84 System, acquired from LoveBiome in connection with our October 2025 acquisition of LoveBiome's critical assets, and which helps to regulate, repair and restore gut health, our TrueScience® line of skin and hair care products and Liquid Collagen, Petandim®, our companion pet supplement formulated to combat oxidative stress in dogs; and AXIO®, our nootropic and energy/hydration drink mixes;

•
Our sales compensation plan and other sales initiatives and incentives; and

•
Our delivery of superior customer service.

As a result, it is vital to our success that we leverage our product development resources to develop and introduce compelling and innovative products and provide opportunities for our independent consultants to sell these products in a variety of markets. We sell our products in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland and Portugal. In addition, we sell our products in a number of countries for personal consumption only. Entering a new market requires a considerable amount of time, resources and continued support. If we are unable to properly support an existing or new market, our revenue growth may be negatively impacted. We closed our market in the Philippines in June 2025 and closed our markets in Hong Kong and Singapore in May 2026.

Our Products

Our products are: the Protandim® line of scientifically validated dietary supplements; the LifeVantage® line of dietary supplements that include the MindBody GLP-1 System®, Omega+, ProBio, IC Bright®, the Rise AM & Reset PM System®, D3+, Daily Wellness; Fat Burn, Prebiotic and Carb Block; our newest activator the P84 System, which helps to regulate, repair and restore gut health; the TrueScience® line of skin and hair care products and Liquid Collagen; our Petandim® companion pet supplement formulated to combat oxidative stress in dogs; and AXIO®, our nootropic and energy/hydration drink mixes. We believe the significant number of customers who regularly and repeatedly purchase our products is a strong indicator of the health benefits of our products.

The Protandim® product line includes Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, and Protandim® NAD Synergizer®. The Protandim® NRF1 Synergizer® is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim® Nrf2 Synergizer® contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body’s natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective antioxidant enzymes, including superoxide dismutase, catalase, and glutathione synthase. The Protandim® NAD Synergizer®

55

was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotinamide adenine dinucleotide), and it has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity, and mood. Use of the three Protandim® products together, marketed as the Protandim® Tri-Synergizer®, has been shown to produce synergistic benefits greater than using the single products on their own.

The LifeVantage® product line includes: the MindBody GLP-1 System®, a dietary supplement that combines two products MB Core® and MB Enhance® designed to support weight loss and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system; ProBio, a dietary supplement designed to support optimal digestion and immune system function; Daily Wellness, a dietary supplement designed to support immune health. IC Bright®, a dietary supplement to help support eye and brain health, reduce eye fatigue and strain, support cognitive functions, and may help support normal sleep patterns; the Rise AM & Reset PM System®, a dietary supplement that uses Timewise Nutrient Delivery™ to provide the body with the right nutrients in the right amounts at the right time; D3+, a dietary supplement that provides vitamin D3, vitamin K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; Daily Wellness, a dietary supplement designed to support immune health; Fat Burn, a dietary supplement designed to support weight-management, that in the past was under the PhysIQ™ line and during fiscal year 2026 was placed under the LifeVantage ® line in the U.S.; Prebiotic, a dietary supplement designed to support a healthy digestive tract, that in the past was under the PhysIQ™ line and during fiscal year 2026 was placed under the LifeVantage ® line in the U.S.; and Carb Block, a dietary supplement drink mix designed to help reduce the impact of carbohydrate-heavy meals by slowing carbohydrate-to-sugar conversion and supporting healthy metabolism that was acquired from LoveBiome as PhytoPower B and rebranded as Carb Block.

The P84 System is our newest patent pending two-product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health, which, in an in vitro study, activated 14 key gut peptides associated with gut health and microbiome support.

Our TrueScience® line of skin and hair care products includes TrueScience® TrueClean Refining Cleanser, TrueScience® TrueRenew Daily Firming Complex, TrueScience® TrueLift Illuminating Eye Cream, TrueScience® TrueHydrate Brightening Moisturizer, TrueScience® TrueTone Perfecting Lotion, TrueScience® TrueProtect Daily Mineral Sunstick SPF 30, TrueScience® Perfecting Lotion, TrueScience® Hand Cream, TrueScience® Invigorating Shampoo, TrueScience® Nourishing Conditioner, TrueScience® Scalp Serum, and TrueScience® Liquid Collagen. TrueScience® Liquid Collagen activates, replenishes, and maintains collagen to support firmness and elasticity from within.

Petandim® is a supplement specially formulated to combat oxidative stress in dogs through Nrf2 activation.

AXIO® is our line of our nootropic and energy/hydration drink mixes formulated to promote alertness and support mental performance.

We sell our products both individually and in stacks. A stack consists of multiple products bundled together that are designed to achieve a specific result. In fiscal year 2026, our stack strategy continued to focus on the brand message of activation. As part of the launch of our latest activator, the P84 System, we introduced the Healthy Edge stack, which includes Protandim® Nrf2 Synergizer® and the P84 System. Results of an in vitro study were released that showed beneficial “activation synergies” when both products were used together, including eight additional detoxification and cellular protection pathway genes, nine gut regulation/repair genes, and the new benefit of activating three circadian rhythm genes and 29 genes that support cellular adaptation.

We continue to offer other popular stacks with products that complement one another with inner activation power for internal benefits that can be felt, external benefits that can be seen, or both.

The following table shows revenue by major product line for the fiscal years ended June 30, 2026 and 2025.

56

Year Ended June 30,
20262025
Protandim® product line$81,98944.9%$95,32841.7%
TrueScience® product line37,85320.7%48,71221.3%
LifeVantage® product line32,25817.7%61,32726.9%
Other30,48616.7%23,16310.1%
Total$182,586100.0%$228,530100.0%

Our revenue for the fiscal years ended June 30, 2026 and 2025 is largely attributed to three product lines, Protandim®, LifeVantage®, and TrueScience®. On a combined basis, these three product lines represent approximately 83.3% and 89.9% of our total net revenue for the fiscal years ended June 30, 2026 and 2025, respectively.

We currently have additional products in development. Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our ability to attract new independent consultants and customers.

Accounts

Because we primarily utilize a direct selling model for the distribution of a majority of our products, the success and growth of our business depends in large part on the effectiveness of our independent consultants to attract and retain customers to purchase our products, and our ability to attract new and retain existing independent consultants. Changes in our product sales are typically the result of variations in product sales volume relating to fluctuations in the number of active independent consultants and customers purchasing our products. The number of active independent consultants and customers is, therefore, used by management as a key non-financial measure.

The following tables summarize the changes in our active accounts by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we define “Active Accounts” as only those independent consultants and customers who have purchased from us at any time during the most recent three-month period, either for personal use or for resale.

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.

Macro cross-references for LFVN

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Inflation (CPI / PCE / PPI), US labor market, Growth & output, Money & trade, Government finances, Sector employment, Industrial orders & inventories, Trade & external.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/LFVN.md · JSON record: /company/LFVN.json · verified financials: JSON / CSV · concise section index: /llms.txt